Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brimarafenib in Advanced or Refractory Solid Tumors
NCT04249843Phase 1Terminated
- Sponsor
- MapKure, LLC
- Start
- Feb 2020
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, open-label trial of Brimarafenib in solid tumor (10 arms), sponsored by MapKure, LLC. Primary endpoints: Number of Participants Experiencing Treatment-Emergent Adverse Events and Serious Adverse Events up to 47 months, Maximum Tolerated Dose at 30 days and 2 more. Started Feb 2020; status: terminated.
02
Drugs
Brimarafenib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04249843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04249843.